Boston Scientific (NYSE:BSX) Price Target Cut to $92.00 by Analysts at Truist Financial

Boston Scientific (NYSE:BSX) had its price objective lowered by Truist Financial from $95.00 to $92.00 in a research note released on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the medical equipment provider’s stock.

A number of other analysts have also commented on BSX. Robert W. Baird lowered their target price on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating for the company in a report on Thursday, February 5th. Weiss Ratings lowered Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, February 4th. Barclays decreased their price objective on Boston Scientific from $136.00 to $124.00 and set an “overweight” rating for the company in a research note on Tuesday, February 3rd. Morgan Stanley lowered their price target on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Finally, TD Cowen cut their price target on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a research report on Monday, February 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $107.18.

Boston Scientific Stock Performance

BSX stock opened at $71.29 on Wednesday. The company has a 50 day moving average price of $80.88 and a 200 day moving average price of $92.56. Boston Scientific has a fifty-two week low of $67.56 and a fifty-two week high of $109.50. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The stock has a market capitalization of $105.78 billion, a PE ratio of 36.75, a price-to-earnings-growth ratio of 1.00 and a beta of 0.69.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. The firm had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business’s quarterly revenue was up 15.9% compared to the same quarter last year. During the same period last year, the company earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Analysts forecast that Boston Scientific will post 2.85 EPS for the current year.

Insider Buying and Selling

In related news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.50% of the company’s stock.

Institutional Investors Weigh In On Boston Scientific

Institutional investors and hedge funds have recently made changes to their positions in the stock. Norges Bank bought a new stake in Boston Scientific during the fourth quarter worth $2,199,395,000. Edgewood Management LLC acquired a new position in shares of Boston Scientific during the 2nd quarter worth about $746,655,000. Parnassus Investments LLC raised its holdings in shares of Boston Scientific by 42,978.9% in the 3rd quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider’s stock valued at $672,128,000 after purchasing an additional 6,868,459 shares during the period. Egerton Capital UK LLP raised its holdings in shares of Boston Scientific by 223.7% in the 3rd quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock valued at $518,660,000 after purchasing an additional 3,671,548 shares during the period. Finally, Maverick Capital Ltd. acquired a new stake in Boston Scientific in the 4th quarter valued at about $280,735,000. Institutional investors own 89.07% of the company’s stock.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific’s European urology portfolio expanded with sacral neuromodulation following the Axonics deal, supporting recurring revenue growth in a defensive medtech category. Sacral neuromodulation broadening Boston Scientific’s European urology portfolio
• Positive Sentiment: Analysts continue to rate BSX as a buy: UBS and Truist trimmed price targets (UBS $120→$105; Truist $95→$92) but retained buy ratings, signaling ongoing analyst conviction even after downward target adjustments. Benzinga analyst notes
• Neutral Sentiment: Coverage pieces position Boston Scientific as a defensive healthcare hedge versus cyclically sensitive sectors, which can attract flows in volatile markets but is not an immediate catalyst. The Highest-Rated Healthcare Stock to Buy Now
• Neutral Sentiment: Industry hires and competitor moves (e.g., Field Medical naming a new CEO with Medtronic experience) are notable for competitive dynamics but are not direct, immediate earnings catalysts for BSX. Field Medical appoints Mark Turco as CEO
• Negative Sentiment: Multiple law firms and plaintiff notices warn Boston Scientific investors of a securities‑class‑action covering purchases from July 23, 2025 to Feb 3, 2026, with a May 4, 2026 lead‑plaintiff deadline — this surge of legal filings/notices increases potential litigation risk and uncertainty. Rosen Law Firm investor alert
• Negative Sentiment: Specific allegations (highlighted by firms such as Levi & Korsinsky) claim executives misrepresented U.S. electrophysiology procedure volumes — if proven, these allegations could lead to meaningful financial and reputational impact. Levi & Korsinsky investor alert

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.